GH Research PLC (NASDAQ:GHRS) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• GH Research PLC (NASDAQ:GHRS) has received an average analyst rating of "Moderate Buy", with seven out of eight analysts giving a buy recommendation.
• The company's stock has a current price target of $32.00 among brokerages, with its shares recently trading at around $13.84.
• GH Research reported earnings of ($0.15) per share for the last quarter, surpassing analysts' expectations, and is involved in developing treatments for psychiatric disorders.

GH Research PLC (NASDAQ:GHRS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $32.00.

A number of research analysts have issued reports on GHRS shares. Cantor Fitzgerald began coverage on GH Research in a report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research report on Friday, May 9th. Guggenheim dropped their target price on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Wall Street Zen upgraded GH Research from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, JMP Securities reissued a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a report on Tuesday, June 24th.

Hedge Funds Weigh In On GH Research

A number of large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock valued at $508,000 after purchasing an additional 3,092 shares in the last quarter. Northern Trust Corp increased its position in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of GH Research during the fourth quarter worth approximately $44,000. Millennium Management LLC purchased a new stake in shares of GH Research during the fourth quarter worth approximately $145,000. Finally, Two Sigma Investments LP purchased a new stake in shares of GH Research during the fourth quarter worth approximately $117,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Trading Down 2.5%

Shares of GH Research stock traded down $0.34 on Friday, reaching $13.50. 84,476 shares of the stock were exchanged, compared to its average volume of 248,770. GH Research has a twelve month low of $6.00 and a twelve month high of $20.50. The business has a 50 day moving average price of $14.01 and a two-hundred day moving average price of $12.12.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. Sell-side analysts anticipate that GH Research will post -0.8 EPS for the current year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).